VRDN Q2 2020 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$168,000-93.3% YoY

Gross Profit

$168,000100.0% margin

Operating Income

-$6M-3794.0% margin

Net Income

-$6M-3830.4% margin

EPS (Diluted)

$-1.82

QoQ Revenue Growth

-79.7%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$623,000

Balance Sheet

Total Assets

$33M

Total Liabilities

$12M

Stockholders' Equity

$21M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$168,000	$3M	-93.3%
Gross Profit	$168,000	-$6M	+102.8%
Operating Income	-$6M	-$9M	+28.7%
Net Income	-$6M	-$9M	+27.7%

Revenue Segments

Grant

$168,000100%